Fragmenting the platelet to reduce metastasis

Blood

Volumn 120, Issue 14, 2012, Pages 2779-2780

  Ware, Jerry ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANGIOGENESIS; BLEEDING; CELL INTERACTION; DRUG MECHANISM; DRUG TARGETING; HEMOSTASIS; HUMAN; METASTASIS; NONHUMAN; NOTE; PLATELET FRAGMENTATION; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTE; THROMBOCYTOPENIA; TUMOR CELL;

EID: 84867320799     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-08-450072     Document Type: Note

References (5)

1. Zhang W, Dang S, Hong T, et al. A humanized single-chain antibody against beta 3 integrin inhibits pulmonary metastasis by preferentially fragmenting activated platelets in the tumor microenvironment. Blood. 2012;120(14):2889- 2898.
2. Leslie M. Cell biology. Beyond clotting: the powers of platelets. Science. 2010;328(5978):562-564.
3. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11(2):123-134.
4. Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000;96(10):3302-3309.
5. Palumbo JS, Talmage KE, Massari JV, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005;105(1):178-185. (Pubitemid 40053080)